葛兰素史克公司（GSK）日前宣布获得吉利德科学公司的一项专利使用权转让协议，该协议的签署使葛兰素史克公司获得独家权利在中国自费市场上市韦瑞德（富马酸替诺福韦二吡呋酯片），用于治疗艾滋病（HIV）。
2009年11月，葛兰素史克公司已经与吉利德科学公司达成了一项专利使用权转让协议。在那项协议中，葛兰素史克公司已经获得了韦瑞德用于治疗成人慢性乙型肝炎在中国的独家上市权利。目前，韦瑞德在中国用于治疗乙肝适应症的3期注册临床试验正在进行中。
作为全球第一个用于艾滋病治疗的核苷酸类似物，韦瑞德是一种新型核苷酸类逆转录酶抑制剂，通过阻断涉及HIV复制的逆转录酶，从而抑制病毒复制。基于韦瑞德的临床有效性和安全性，2001年，美国批准韦瑞德用于与其他抗逆转录病毒药物合用治疗HIV。至今，已有包括中国在内的100多个国家批准韦瑞德用于与其他抗病毒药物合用治疗HIV，是多个治疗指南推荐使用的一线抗HIV药物。作为处方药，韦瑞德必须凭专业医生处方获得。出于用药的安全性和有效性的考虑，患者必须去正规的医院接受专业医生的治疗和处方。
艾滋病不治会早死，早治才康复 艾滋病不治会早死，早治才康复 艾滋病不治会早死，早治才康复 艾滋病不治会早死，早治才康复
 |
| 图示∶2011年5月正式出版的《中国特色医疗金鉴》登载的刘君主任及其机构事迹 |
| |
|
|
Wei Ruide can be used for AIDS treatment
2011/10/24 00:00:00 source: YNET.com North Youth
GlaxoSmithKline (GSK) today announced that Gilead Sciences Inc. received a patent licensing agreement, the signing of the agreement GSK received exclusive rights in China at their own expense markets Weirui De (fumarate for Norfolk Wei two topiramate tablets furosemide esters), for the treatment of AIDS (HIV).
November 2009, GlaxoSmithKline and Gilead Sciences Inc. has entered into a patent licensing agreement. In that agreement, GlaxoSmithKline has received Weirui De for the treatment of adults with chronic hepatitis B in China's exclusive listing rights. At present, Wei Ruide for the treatment of hepatitis B in China indications 3 registration clinical trials are underway.
As the world's first nucleotide analogue for the treatment of AIDS, Wei Ruide is a new nucleotide reverse transcriptase inhibitor, involved in HIV replication by blocking reverse transcriptase, thereby inhibiting viral replication. Based on Weirui De clinical efficacy and safety in 2001, the United States and other approved Wei Ruide for combination antiretroviral treatment of HIV. To date, including China, more than 100 countries approved the Wei Ruide for combination therapy with other antiviral HIV, treatment guidelines recommend the use of multiple first-line anti-HIV drugs. As prescription drugs, Wei Ruide must obtain a doctor's prescription with the professional. For drug safety and efficacy considerations, the patient must go to a regular hospital for professional medical treatment and prescription.
